BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29371584)

  • 1. Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung.
    Shi M; Xu H; DiPoto Brahmbhatt A; Gonzalez-Toledo E; Georgescu MM
    Am J Case Rep; 2018 Jan; 19():99-104. PubMed ID: 29371584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells.
    Pareja F; Crapanzano JP; Mansukhani MM; Bulman WA; Saqi A
    Cancer Cytopathol; 2015 Mar; 123(3):162-70. PubMed ID: 25557162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare co-existence of mutation in KRAS and ALK gene re-arrangement in an adenocarcinoma patient--a case report.
    Homa I; Sawicki M; Wojas-Krawczyk K; Nicoś M; Mlak R; Powrózek T; Krawczyk P; Przybylski P; Czekajska-Chehab E; Milanowski J
    Anticancer Res; 2014 Jul; 34(7):3701-5. PubMed ID: 24982390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report.
    Yuan C; Ma MJ; Parker JV; Mekhail TM
    Am J Case Rep; 2017 Jul; 18():799-804. PubMed ID: 28713152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
    Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy.
    Incharoen P; Reungwetwattana T; Saowapa S; Kamprerasart K; Pangpunyakulchai D; Arsa L; Jinawath A
    World J Surg Oncol; 2016 May; 14():139. PubMed ID: 27142166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor.
    Nakajima M; Uchiyama N; Shigemasa R; Matsumura T; Matsuoka R; Nomura A
    Intern Med; 2016; 55(21):3151-3153. PubMed ID: 27803410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features.
    Possidente L; Landriscina M; Patitucci G; Borgia L; Lalinga V; Vita G
    Med Oncol; 2017 May; 34(5):76. PubMed ID: 28364271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK-rearranged adenocarcinoma with extensive mucin production can mimic mucinous adenocarcinoma: clinicopathological analysis and comprehensive histological comparison with KRAS-mutated mucinous adenocarcinoma.
    Cha YJ; Han J; Hwang SH; Lee TB; Kim H; Zo JI
    Pathology; 2016 Jun; 48(4):325-9. PubMed ID: 27114375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma.
    Jeong CJ; Lee HY; Han J; Jeong JY; Lee KS; Choi YL; Choi JY
    Clin Nucl Med; 2015 Jan; 40(1):e34-9. PubMed ID: 25243942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
    Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L
    J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma.
    Tao H; Cai Y; Shi L; Tang J; Liu Z; Wang Z; Bai L; Liu Z
    Thorac Cancer; 2017 Jan; 8(1):8-15. PubMed ID: 27779369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
    Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
    BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
    Zhao J; Zhou J; Chen Z; Wang B; Zhang X; Zhou J; Ding W
    Int J Clin Exp Pathol; 2015; 8(3):3344-8. PubMed ID: 26045865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.
    Caumont C; Veillon R; Gros A; Laharanne E; Bégueret H; Merlio JP
    Lung Cancer; 2016 Feb; 92():15-8. PubMed ID: 26775590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK gene rearranged lung adenocarcinomas: molecular genetics and morphology in cohort of patients from North India.
    Bal A; Singh N; Agarwal P; Das A; Behera D
    APMIS; 2016 Oct; 124(10):832-8. PubMed ID: 27500967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.
    Levacq D; D'Haene N; de Wind R; Remmelink M; Berghmans T
    Lung Cancer; 2016 Dec; 102():38-41. PubMed ID: 27987586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.